Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions
Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?
Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model
The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability
Managing the Growing Expansion of Copay Accumulators
Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
Emerging Trends in PBM Restrictions on Commercial Copay Assistance
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Rethink: Payer Strategies for Commercializing Cell and Gene Therapies
Insights from managed care executives on the future of coverage and outcomes evaluation.